ICOTF Stock UPDATES Ico Therapeutics (ICOTF) 0.0540 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board

Aug 3, 2014 at 3:58 PM

Ico Therapeutics (ICOTF) 0.0540 $ICOTF

iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity.

Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"

appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee.

iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:

iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
CNW Group - Mon Jun 09, 7:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) today announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study, conducted in collaboration with JDRF, evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).

Immune Appoints Gad Berdugo to Board of Directors and Karin Hehenberger, M.D., Ph.D to Senior Vice President
GlobeNewswire - Fri Jun 06, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"

appointed Mr. Gad Berdugo as new independent director and Karin Hehenberger, M.D., Ph.D., as Senior Vice President, Medical Affairs and Corporate Communications.

iCo Therapeutics Announces First Quarter 2014 Financial Results
PR Newswire - Thu May 29, 4:00PM CDT
iCo Therapeutics ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"

.

Immune Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed May 21, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) and (Nasdaq:IMNP) ("Immune" or "the Company"

announced today its financial results for the three month period ended March 31, 2014.

Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.

Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.

iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
CNW Group - Wed Mar 05, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public.

iCo Therapeutics Announces DTC Approval
PR Newswire - Tue Feb 25, 12:15PM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC"

, thus providing the Company with DTC eligibility.

IIROC Trade Resumption / L'OCRCVM permet la reprise de la négociation - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 9:20AM CST
Trading resumes in / Reprise des negociations pour:

iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
PR Newswire - Mon Jan 27, 9:03AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) announced today that it has closed its previously announced overnight marketed offering of equity securities (the "Offering"

. Pursuant to the Offering, iCo issued 16,206,483 units of the Company ("Units"

at a price of $0.4165 per Unit for aggregate gross proceeds of C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share"

and three-quarters of one common share purchase warrant (each whole warrant, a "Warrant"

. Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one Common Share for a period of five years following the date of issuance of the Warrant.

IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 8:43AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :

iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
PR Newswire - Wed Jan 22, 7:42AM CST
iCo Therapeutics Inc. ("iCo" or the "Company"

(TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today that the Company has priced its previously announced overnight marketed offering of equity securities (the "Offering"

. Pursuant to the Offering, iCo will issue an aggregate of up to 16,206,483 units of the Company ("Units"

at a price of C$0.4165 per Unit for aggregate gross proceeds of approximately C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share"

and three-quarter of one common share purchase warrant (each whole warrant, a "Warrant"

. Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share"

for a period of five years following the closing of the Offering.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

From Kitchen Experiment to U.S. Debut Here's a story that barely fits the tight mold of your typical business textbook. Hair Syrup, born from the brain of a university student tinkering at her kitchen table, is about to make waves across the pond. Lucie Macleod did what many dream of—she took a DIY hair oil project and spun it into a multimillion-dollar brand, now set...

Aflac's $200M Milestone in Cancer Charity Support

Pioneering Efforts Across Decades Here’s an effort that bucks the usual corporate talk. Aflac, the supplemental insurance giant, isn’t just mumbling about its mission; it's doing the heavy lifting in the fight against childhood cancer and blood disorders. With over $200 million in contributions poured into the cause over more than 30 years, they're putting the capital...

Cove Capital Secures $9.96M for Debt-Free Logistics DST

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

ABC Honors 2026 Spirit of the Heart Leaders

Celebrating Champions of Cardiovascular Health In a world where accolades often feel as cold as the stock market after a crash, it’s heartening to see genuine recognition for those who are making actual, lasting impact. On October 3, 2026, the Association of Black Cardiologists (ABC) will hold its annual Spirit of the Heart Awards at none other than Cipriani Wall...

EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

South Florida Donor Network Honors 52 Heroic Donors

A Heartfelt Tribute to Lifesavers You ever been to a gathering that reminds you how deeply human connections run? That's what happened at The Diplomat Beach Resort in Hollywood. South Florida Donor Network (SFDN) pulled together a ceremony honoring 52 donor heroes whose legacies beat strong through the recipients living thanks to their gifts. An Event Worth Attending...

Push Notification Security Transforms Healthcare IT Support

Cutting the Fat on IT Help Desk Bottlenecks Healthcare IT teams are fighting an uphill battle with password resets, a mundane task consuming up to half of all help desk calls. It's like trying to stop a leaking dam with duct tape. For health systems, these calls aren't just a minor annoyance—they're a full-fledged budget hog. Try telling a CIO that an agent-friendly...

CUBEX Lights Up Veterinary Care with Mini Essential

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Are FULC, WEAV, TECH Shareholders Getting a Raw Deal?

Pocketing Insider Gains Amidst Shareholder Concerns Let me tell you, it smells like another day in the financial jungle where insiders might be feasting while the regular Joe shareholders are left nibbling on crumbs. Fulcrum Therapeutics, Weave Communications, and Bio-Techne are in the crosshairs for deals that may favor those on the inside track over you and me, the...